INBX NASDAQ
Inhibrx Biosciences Inc.
1W: -2.6%
1M: -22.4%
3M: -0.1%
YTD: +29.2%
1Y: +185.4%
$96.99
-0.94 (-0.96%)
Weekly Expected Move ±7.5%
$82
$90
$97
$104
$112
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
Bank of America Corp DE Makes New $79.70 Million Investment in Inhibrx Biosciences, Inc. $INBX
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
Inhibrx, Eikon rise after insider buying
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial
Inhibrx Biosciences (INBX) Earnings Put Its Valuation Back In Focus - simplywall.st
Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target - Investing.com
Inhibrx Biosciences (INBX) Earnings Put Its Valuation Back In Focus - Sahm
Inhibrx (INBX): Viking Global group discloses 9.3% beneficial ownership stake - Stock Titan
Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position - Stock Titan
Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing - Stock Titan
Inhibrx Reports Second Quarter 2026 Financial Results
FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart - Stock Titan
Inhibrx Biosciences (INBX) sees 5.9% ownership reported by Bank of America - Stock Titan
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act (NASDAQ:INBX) - Seeking Alpha
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
Inhibrx Gets $100 Million Now; Lenders May Fund $225 Million More - Stock Titan
Price-Driven Insight from (INBX) for Rule-Based Strategy - Stock Traders Daily
What is Inhibrx Biosciences, Inc. (INBX) stock_business overview_development history - Bitget
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
Does Inhibrx Biosciences' (INBX) Shift Into Russell Growth Indexes Reframe Its Core Investment Story? - simplywall.st
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice - Yahoo Finance
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
Inhibrx Biosciences (INBX) Following Russell Reshuffle With Valuation Still Hard To Pin Down - simplywall.st
How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors - simplywall.st
Inhibrx Biosciences, Inc. Actuals & Estimates (NASDAQ:INBX) - TradingView
10 small-cap U.S. healthcare stocks with the strongest momentum grades
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
FDA review begins for potential first drug for aggressive bone cancer - Stock Titan
Inhibrx Reports First Quarter 2026 Financial Results
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study - Yahoo Finance
Inhibrx Reports First Quarter 2026 Financial Results - PR Newswire
Should Positive INBRX-106 Phase 2 Head and Neck Data Require Action From Inhibrx Biosciences (INBX) Investors?
Merck Broadens KEYTRUDA Collaborations As Patent Expiry Pressure Builds
Should Positive INBRX-106 Phase 2 Head and Neck Data Require Action From Inhibrx Biosciences (INBX) Investors? - Yahoo Finance
Should Positive INBRX-106 Phase 2 Combo Data in Head and Neck Cancer Require Action From Inhibrx Biosciences (INBX) Investors? - simplywall.st
Inhibrx Biosciences Reports Positive Interim Phase 2 Results - TipRanks
Why Is Inhibrx Biosciences Stock Trading Higher Today? - Inhibrx Biosciences (NASDAQ:INBX) - Benzinga
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study
Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
This Biotech Stock Surges After Positive Cancer Trial Results. What to Know.
Inhibrx Biosciences (INBX) Stock Soars 17% Following Impressive Phase 2 Cancer Data - Blockonomi
Inhibrx Biosciences (INBX) Stock Jumps 17% on Positive Cancer Trial Results - CoinCentral
Cancer trial: Inhibrx combo lifts head and neck response rate to 44% - Stock Titan
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
A Look At Inhibrx Biosciences (INBX) Valuation As Investors Await Phase 2 HexAgon Webcast Results - Sahm
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
This Biotech Stock Surges After Positive Cancer Trial Results. What to Know. - Barron's
12 Health Care Stocks Moving In Friday's After-Market Session
Inhibrx rises on upcoming interim mid-stage data for head and neck cancer asset
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
Inhibrx to share interim Phase 2 head and neck cancer data Monday - Stock Titan
Inhibrx Biosciences, Inc. Common Stock (INBX) Stock Price Today: $97.10 - Gotrade
Assessing Inhibrx Biosciences (INBX) Valuation After Ozekibart Data And Regulatory Momentum
Assessing Inhibrx Biosciences (INBX) Valuation After Ozekibart Data And Regulatory Momentum - Yahoo Finance
Inhibrx Biosciences president granted 50K options | INBX Insider Trading - Stock Titan
Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans
Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans - Yahoo Finance
Understanding Momentum Shifts in (INBX) - Stock Traders Daily
Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer
INBX stock hit record highs: Cancer therapies reportedly draw big pharma interest - MSN
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
[ARS] Inhibrx Biosciences, Inc. SEC Filing - Stock Titan
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study - Yahoo Finance
Should I buy Inhibrx Biosciences, Inc. (INBX) - Zacks Investment Research
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
12 Health Care Stocks Moving In Wednesday's Intraday Session
Top Midday Stories: GE Vernova Shares Gain on Strong Q1 Earnings, Guidance; Vertiv Lifts Guidance After Q1 EPS, Revenue Beats, Shares Fall
GE Vernova, Boston Scientific, Intuitive Surgical And Other Big Stocks Moving Higher On Wednesday
Dow Jumps Over 400 Points; Boeing Posts Upbeat Q1 Results
Inhibrx cancer drug reportedly drawing interest of Merck and rivals
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
INBX jumps after ozekibart colorectal cancer update and regulatory progress | INBX Stock News - Quiver Quantitative
Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue (NASDAQ:INBX) - Seeking Alpha
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
87% disease control lifts Inhibrx drug in late-line colorectal cancer - Stock Titan
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Late-line colon cancer study update arrives Tuesday in Inhibrx webcast - Stock Titan
Inhibrx gains as Stifel issues new Buy based on lead assets
Coinbase downgraded, Deere upgraded: Wall Street's top analyst calls
This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
SG Americas Securities LLC Invests $1.27 Million in Inhibrx Biosciences, Inc. $INBX
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results - PR Newswire
Boothbay Fund Management LLC Boosts Holdings in Inhibrx Biosciences, Inc. $INBX
7,388 Shares in Inhibrx Biosciences, Inc. $INBX Acquired by Dynamic Technology Lab Private Ltd
Inhibrx Announces Participation in Upcoming Scientific Conference
Inhibrx Announces Participation in Upcoming Scientific Conference - PR Newswire
Inhibrx Biosciences, Inc. $INBX Shares Sold by Credit Industriel ET Commercial
Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts
Why Inhibrx's Recent Strength May Not Be Built to Last
Inhibrx (INBX): Assessing a Lofty Valuation After Fresh INBRX-106 and Ozekibart Milestone Updates
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program - PR Newswire